Connor Iapoce

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

Pre-pregnancy overweight and obesity were not linked to an increased prevalence of iron deficiency or anemia during pregnancy in a US population.

A real-world post-authorization safety study identified no new safety signals compared with the phase 2/3 clinical trial of rpFVIII for acquired hemophilia A.

Lifetime statin treatment increased quality-of-life-adjusted survival in men and women aged ≥70 years with and without previous CVD in the United Kingdom.

ATSN-101 was well tolerated 12 months after treatment and demonstrated on average, a 100-fold improvement in vision, with some improved by 10,000-fold.

Nearly 19% of dementia cases were attributable to ≥1 vision impairment in a nationally representative sample of older US adults.

An investigation into basic and instrumental activities of daily living in older female patients found greater reliance in those with anemia.

A systematic review found a higher prevalence of acute pancreatitis in individuals with the HbSS genotype, though a meta-analysis could not be performed.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Host Veeral Sheth, MD is joined by John Sheets, PhD, the president, CEO, and co-founder of Pantheon Vision, an early research-stage organization working to develop bioengineered solutions to eliminate corneal blindness.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.

This August 2024 month in review highlights updates to the ophthalmic pipeline, metformin for geographic atrophy, and decreasing rates of postoperative endophthalmitis in the US.

Sara Diaz Saravia, MD, discusses a study from ESC Congress 2024 examining the utility of cancer history in women as a predictor of subclinical atherosclerosis.

Women with endometriosis experienced a 20% greater risk of cardiac outcomes compared with women without endometriosis.

Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.

Panretinal photocoagulation followed by anti-VEGF injections increases the likelihood of PPV, compared with anti-VEGF therapy first.

After an initial switch to faricimab, anatomical measures showed improvement while no functional improvement was identified in real-world data.

A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.

Brolucizumab achieved non-inferiority in mean BCVA change to aflibercept in eyes with nAMD but demonstrated a higher incidence of IOI at 2 years.